Данная работа является продолжением статьи, опубликованной в предыдущем номере журнала «CardioСоматика», где подробно были представлены плейотропные (дополнительные) эффекты статинов (с акцентом на аторвастатин), касающиеся их разнообразного воздействия на сердечно-сосудистую систему. В настоящей статье автор представил плейотропные эффекты некардиального характера. Подробно разбираются клинические эффекты статинов на разнообразную патологию других (кроме сердца и сосудов) органов и систем. В частности, влияние статинов на заболевания почек, печени (билиарный цирроз), ревматоидный артрит, пневмонию, на разные деменции, включая болезнь Альцгеймера, на сепсис и бактериемию, включая синдром приобретенного иммунодефицита. Обсуждаются степень доказательности этих эффектов при разных заболеваниях, возможные механизмы действия и их клиническая значимость.
Ключевые слова: статины, некардиальные плейотропные эффекты, статины и заболевания почек, статины и билиарный цирроз печени, статины и ревматоидный артрит, статины и пневмония, статины и деменции, статины и сепсис, статины и синдром приобретенного иммунодефицита.
________________________________________________
This paper is a continuation of the paper published in the previous issue of the journal «CardioSomatics», which detailed the pleiotropic (additional) effects of statins (with emphasis on atorvastatin), which concerned their varied action on the cardiovascular system. In this paper, the author presents their noncardiac pleiotropic effects. The clinical effects of statins on various diseases of other organs and system (other than the heart and vessels) are examined in detail. Among other things, statins affect diseases of the kidney, liver (biliary cirrhosis), rheumatoid arthritis, pneumonia, various dementias, including Alzheimer’s disease, on sepsis and bacteremia, including acquired immunodeficiency syndrome. The evidence of these effects in various diseases, possible mechanism of action, and their clinical significance are discussed.
Key words: statins; noncardiac pleiotropic effects; statins and renal diseases; statins and biliary cirrhosis, statins and rheumatoid arthritis; statins and pneumonia; statins and dementias; statins and sepsis; statins and acquired immunodeficiency syndrome.
1. Shepherd J, Kastelein JJ, Bittner V et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) stady. Clin J Am Soc Nephrol 2007; 2 (6): 1131–9.
2. Colhoun HM, Betteridge DJ, Durrington PN et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54 (5): 810–9.
3. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377 (9784): 2181–92.
4. Wu Y, Wang Y, An C et al. Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. Circ J 2012; 76 (5): 1259–66.
5. Renke M, Tylicki L, Rutkowski P. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease-placebo controlled, randomised, cross-over study. Acta Biochim Pol 2010; 57 (4): 547–52.
6. Shepherd J, Kastelein JP, Bittner VA et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008; 83 (8): 870–9.
7. März W, Genser B, Drechsler C et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 6 (6): 1316–25.
8. Rutter MK, Prais HR, Chariton-Menys V et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of hidh-vs. low-dose atorvastatin. Diabet Med 2011; 28 (1): 100–8.
9. Stavroulopoulos A, Petras D, Kakavas I et al. Monocyte expression of adhesion molecules during low-and high-flux polysulfone hemodialysis and the effect of atorvastatin administration. Blood Purif 2010; 29 (3): 274–9.
10. Zhao JL, Yang YH et al. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 2007; 24.
11. Li W, Fu X, Wang Y et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology 2012.
12. Yigit F, Muderrisoglu H et al. Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure. Jpn Heart J 2004; 45 (6): 959–68.
13. Baigent C, Landray M, Warren M. Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Curr Opin Nephrol Hypertens 2004; 13 (6): 601–56.
14. Kurihara T, Akimoto M, Abe K et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 1993; 15 (5): 890–8.
15. Kolouchova G, Brcakova E, Hirsova P et al. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. J Gastroenterol Hepatol 26: 1544–51. Doi: 10.1111/j.1440-1746.2011.06748.x
16. Del Puppo M, Galli Kienle M, Crosignani A et al. Cholesterol metabolism in primary biliary cirrhosis during Simvastatin and UDCA administration. J Lipid Res 2001; 42 (3): 437–41.
17. Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010; 55 (7): 2086–8.
18. Stojakovic T, Claudel T, Putz-Bankuti C et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209 (1): 178–83.
19. Bateson MC. Simvastatin and ursodcoxychlolic acid for rapid gallstone dissolution. Lancet 1990; 336: 1196–9.
20. Pham T, Gossec L, Constantin A et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. J Bone Spine 2006; 73 (4): 379–87.
21. Blaschke S, Viereck V, Schwarz G et al. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 2009; 38 (4): 235–9.
22. Kumar VL, Guruprasad B, Wahane VD. Atorvastatin exhibits anti-inflammatory and anti-oxidant properties in adjuvant-induced monoarthritis. Inflammopharmacology 2010; 18 (6): 303–8.
23. Kim JY, Lee EY, Lee EB et al. Atorvastatin inhibit osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Res Ther 2012; 14 (4): 187.
24. Tam LS, Li EK, Shang Q et al. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis:a randomized controlled pilot trial. Scand J Rheumatol 2001; 40 (6): 411–21.
25. De Vera MA, Choi H, Abrahamowicz M et al. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis:a population-based study. Arthritis Care Res (Hoboken) 2012; 64 (6): 809–16.
26. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004; 363 (9426): 2015–21.
27. EI-Barbary AM, Hussein MS, Rageh EM et al. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol 2011; 38 (2): 229–35.
28. Никитина Н.М., Ребров А.П. Применение аторвастатина у больных ревматоидным артритом и гиперлипидемией. Кардиология. 2009; 49 (9): 21–6.
29. Титов В.Н., Попкова Т.В., Новикова Д.С. и др. Сравнительный анализ противовоспалительного эффекта аторвастатина при ИБС и ревматоидном артрите. Кардиология. 2008; 48 (9): 4–8.
30. Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract 2011; 61 (592): e742–8.
31. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001; 21 (6): 767–9.
32. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006; 40 (10): 1880–3.
33. Barone E, Cenini G, Di Domenico F et al. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 2011; 63 (3): 172–80.
34. Zheng C, Azcutia V, Aikawa E et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J 2012.
35. Tendolkar I, Enajat M, Zwiers MP et al. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. Int J Geriatr Phychiatry 2012; 27 (1): 49–58.
36. Masse I, Bordet R, Deplanque D, AL Khedr A. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005; 76 (12): 1624–9.
37. Sano M, Bell KL, Galasko D et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 9, 77 (6): 556–63.
38. Carlsson CM, Gleason CE, Hess TM et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J Alzheimers Dis 2008; 13 (2): 187–97.
39. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23 (7): 871–80.
40. Sheng X, Murphy MJ, Macdonald TM, Wei L. The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. BMC Public Health 2012; 30 (12): 712.
41. Schmidt H, Hennen R, Keller A et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006; 32 (8): 1248–51.
42. Martin CP, Talbert RL, Burgess DS et al. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 2007; 27 (1): 20–6.
43. Yang KC, Chien JY, Tseng WK et al. Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 2007; 25 (5): 494–501.
44. Tseng MY, Hutchinson PJ, Czosnyka M et al. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurismal subarachnoid hemorrhage. Stroke 2007; 38 (5): 1545–50.
45. Thomsen RW, Hundborg HH, Johnsen SP et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006; 34 (4): 1080–6.
46. Almod Y, Novak V, Eisinger M et al. The effect of statin therapy on infection- related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35 (2): 372–8.
47. Gupta R, Plantinga LC, Fink NE et al. Statin use and sepsis events (corrected) in patients with chronic kidney disease. JAMA 2007; 297 (13): 1455–64.
48. Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169 (18): 1658–67.
49. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008; 61 (2): 362–4.
50. Acheampong E, Parveen Z, Mengistu A et al. Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro. J Virol 2007; 81 (3): 1492–501.
51. Benesic A, Zilly M, Kluge F et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004; 32 (4): 229–33.
Авторы
Д.М.Аронов, М.Г.Бубнова*
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава РФ, Москва
*mbubnova@gnicpm.ru
________________________________________________
D.M.Aronov, M.G.Bubnova*
State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscow
*mbubnova@gnicpm.ru